The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited
The 5th Commercializing Flow Chemistry Summit marks a pivotal year, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing ind
